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Abstract
Background: Arcanobacterium haemolyticum is an emerging human pathogen that causes pharyngitis, wound
infections, and a variety of occasional invasive diseases. Since its initial discovery in 1946, this Gram positive
organism has been known to have hemolytic activity, yet no hemolysin has been previously reported. A.
haemolyticum also displays variable hemolytic activity on laboratory blood agar that is dependent upon which
species the blood is derived.
Results: Here we describe a cholesterol-dependent cytolysin (CDC) secreted by A. haemolyticum, designated
arcanolysin (aln), which is present in all strains (n = 52) tested by DNA dot hybridization. Among the known CDCs,
ALN is most closely related to pyolysin (PLO) from Trueperella (formerly Arcanobacterium) pyogenes. The aln probe,
however, did not hybridize to DNA from T. pyogenes. The aln open reading frame has a lower mol %G+C (46.7%)
than the rest of the A. haemolyticum genome (53.1%) and is flanked by two tRNA genes, consistent with probable
acquisition by horizontal transfer. The ALN protein (~ 64 kDa) contains a predicted signal sequence, a putative PEST
sequence, and a variant undecapeptide within domain 4, which is typically important for function of the toxins. The
gene encoding ALN was cloned and expressed in Escherichia coli as a functional recombinant toxin. Recombinant
ALN had hemolytic activity on erythrocytes and cytolytic activity on cultured cells from human, rabbit, pig and horse
origins but was poorly active on ovine, bovine, murine, and canine cells. ALN was less sensitive to inhibition by free
cholesterol than perfringolysin O, consistent with the presence of the variant undecapeptide.
Conclusions: ALN is a newly identified CDC with hemolytic activity and unique properties in the CDC family and
may be a virulence determinant for A. haemolyticum.
Background
Arcanobacterium haemolyticum, a Gram positive, pleo-
morphic rod, causes wound infections and pharyngitis
and can occasionally cause more severe invasive diseases
such as endocarditis, meningitis, septic arthritis, pneumo-
nia and osteomyelitis in humans [1]. There is strong epi-
demiologic evidence for A. haemolyticum being the only
or primary isolate from throat specimens of some
humans with pharyngitis [1-4] and these data suggest
that the number of cases per year of A. haemolyticum-
mediated pharyngitis is ~240,000-480,000 with 0.5-1 mil-
lion lost work days in the United States. The organism,
previously in the Corynebacterium genus, was classified
as the first member of the genus Arcanobacterium [5].
The other members of the genus are uncommonly iso-
lated and remain largely uncharacterized, with the excep-
tion of Trueperella (Arcanobacterium) pyogenes, which is
an important opportunistic livestock pathogen [6].
Little is known about A. haemolyticum virulence fac-
tors with the exception of a phospholipase D (PLD) [7],
which causes dermonecrosis [8]. We recently described
the ability of PLD to reorganize host membrane lipid
rafts, leading to enhanced bacterial adhesion [9].
Furthermore, A. haemolyticum w a sa b l et oi n v a d eH e L a
cells and once intracellular, PLD was able to kill host
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any medium, provided the original work is properly cited.cells via direct necrosis [9]. These effects could poten-
tially lead to bacterial dissemination to deeper tissues.
It is thought that clinical microbiology laboratories
often miss A. haemolyticum in clinical specimens due to
the organism’s weak hemolytic activity on the com-
monly-used sheep blood agar, and therefore it may be
misinterpreted as commensal diphtheroids and the iso-
late discarded. However, this organism displays more
pronounced hemolysis on human and rabbit blood
[10,11]. The organism has been known to have hemoly-
tic activity since its initial discovery in 1946 [12], yet no
bona fide hemolysin has been previously reported. PLD
itself is not directly hemolytic, but causes synergistic
hemolysis with bacteria that express cholesterol oxidase
[13], prompting a search for the A. haemolyticum hemo-
lysin. Possible clues to the identity of the A. haemolyti-
cum hemolysin come from studies on the hemolytic
bacterium T. pyogenes, which is closely related to A.
haemolyticum. T. pyogenes expresses PLO, a member of
the cholesterol-dependent cytolysin (CDC) toxin family,
as its primary virulence factor and this molecule is a
hemolysin [14]. Thus, we hypothesized that the hemoly-
tic activity expressed by A. haemolyticum was due to
the presence of an uncharacterized CDC.
Here we report the identification and characterization
of a CDC from A. haemolyticum, designated arcanolysin
(ALN). We show that ALN has several distinct struc-
tural features among the CDC family and demonstrate
that ALN is cholesterol-dependent and provide evidence
that ALN has variable hemolytic and cytotoxic activity
against mammalian cells from different species. We pro-
pose ALN is the long, sought-after hemolysin.
Methods
Bacteria and growth conditions
ATCC 9345 is the A haemolyticum type strain. The
other A. haemolyticum strains used in this study were
archival isolates obtained from diverse human clinical
cases (Table 1). A. haemolyticum and Escherichia coli
strains were grown as previously described [9].
DNA techniques
E. coli DH5aMCR plasmid DNA extraction, transforma-
tion, DNA restriction, ligation and agarose gel electro-
phoresis were by standard methods [15]. DNA
hybridization was performed using the DIG DNA Label-
ing and Detection Kit (Roche). PCR DNA amplification
was performed using Vent DNA polymerase (NEB) for
35 cycles of 1 min at 94°C, 1 min at 50°C and 1 min/kb
at 72°C, with a final extension step of 72°C for 7 min.
Nucleotide sequence determination and analysis
Prior to the recent GenBank deposit of the 1.986 MB
genome from strain ATCC9345 (= DSM20595 = 11018)
[16], we sequenced the same strain to > 20× coverage
(454 Life Sciences), with ~1.945 MB of unique sequence
(> 98% complete) with essentially identical sequence
data. A translated ORF with amino acid similarity to
CDCs, Arch_1062, was identified within this sequence.
Oligonucleotide primers flanking this ORF were used to
amplify the region by PCR. The nucleotide sequence
was confirmed by automated DNA sequencing of both
strands. The aln sequence data and flanking regions
were submitted to the GenBank/EMBL/DDBJ databases
under accession number FJ785427.
Database searches were performed using the BlastX
and BlastP algorithms [17]. tRNA sequences were iden-
tified using the tRNAscan-SE program [18]. Signal
sequence prediction was performed using SignalP [19].
Transcriptional terminators were identified using mfold
[20]. Multiple sequence alignments were performed
using CLUSTAL W [21], and tree construction was with
the neighbor-joining algorithm and midpoint rooting,
carried out in MacVector version 12.0.3 (MacVector,
Inc.). PEST sequence prediction used the pestfind algo-
rithm http://emboss.bioinformatics.nl/cgi-bin/emboss/
epestfind.
Cloning and purification of a recombinant, 6xHis tagged-
ALN (His-ALN)
The aln gene, without the signal sequence, was ampli-
fied from A. haemolyticum ATCC9345 genomic DNA
by PCR with His-ALNF (5’-CCCGGCGTTGCGGATC-
CAGTTGACGC-3’)a n dA L N 5( 5 ’-GGACCTTCTC-
GAGTATGTATCACTC-3’)e n c o d i n gBamHI and XhoI
sites (underlined in the primer sequence), respectively.
These primers amplified a 1,669 bp product. The PCR
fragment was digested with BamHI-XhoI and cloned
into pTrcHisB (Invitrogen), to generate pBJ51, which
encoded the 63.7 kDa His-ALN. The final His-ALN
translational fusion protein thus has the
MWVGSQKHYFFYQDRGKIMTRRFLATVAGTALLA-
GAFAPGVAFG signal sequence removed and replaced
with the sequence from the vector that leads to
MGGSHHHHHHGMASMTGGQQMGR-
DLYDDDDKDP (6 His underlined). No other ALN
native amino acids were removed. Cultures for purifica-
tion of His-ALN were grown and lysed as described [9].
His-ALN was purified from the soluble cell fraction
using TALON Metal Affinity Resin, as described (Clon-
tech). His-ALN was eluted from the resin with 50 mM
imidazole, 20 mM Tris-HCl, 100 mM NaCl, pH 8.0 (elu-
tion buffer). Total protein concentration was determined
using Bradford Protein Assay Reagent (Bio-Rad).
For some experiments ALN was amplified from ATCC
9345 DNA using the primers ALN26-F
(GCCGCCGCTAGCGTTGACGCTTCAACACAAACC-
GATCC) and ALN-R (GCCGCCCTCGAGTCACTCG
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Strain
(all A. haemolyticum except as noted)
Relevant characteristics Source
AhS1 Biotype S*; wound infection; 73 year old male; 1991 Petteri Carlson
AhS2 Biotype S; paronychia; 16 year old male; 1991 Petteri Carlson
AhS3 Biotype S; wound infection; 11 year old male; 1991 Petteri Carlson
AhS4 Biotype S; infected leg ulcer; 47 year old male; 1991 Petteri Carlson
AhS5 Biotype S; wound infection; 64 year old male; 1991 Petteri Carlson
AhS6 Biotype S; wound infection; 43 year old male; 1991 Petteri Carlson
AhS7 Biotype S; infected leg ulcer; 68 year old female; 1991 Petteri Carlson
AhS8 Biotype S; wound infection; 62 year old male; 1991 Petteri Carlson
AhS9 Biotype S; wound infection; 38 year old male; 1991 Petteri Carlson
AhS10 Biotype S; paronychia; 21 year old male; 1991 Petteri Carlson
AhS11 Biotype S; pharyngitis; 3 year old male; 1991 Petteri Carlson
AhS12 Biotype S; pharyngitis; 23 year old female; 1992 Petteri Carlson
AhS13 Biotype S; pharyngitis; 28 year old female; 1992 Petteri Carlson
AhS14 Biotype S; pharyngitis; 23 year old female; 1992 Petteri Carlson
AhS15 Biotype S; pharyngitis; 20 year old male; 1992 Petteri Carlson
AhS16 Biotype S; sinusitis; 41 year old male; 1990 Petteri Carlson
AhS17 Biotype S; sinusitis; 65 year old female; 1991 Petteri Carlson
AhS18 Biotype S; pharyngitis; 12 year old male; 1992 Petteri Carlson
AhS19 Biotype S; pharyngitis; 20 year old female; 1992 Petteri Carlson
AhS20 Biotype S; pharyngitis; 34 year old male; 1992 Petteri Carlson
AhS21 Biotype S; peritonsillar abscess; 15 year old male; 1996 Petteri Carlson
AhS22 Biotype S; pharyngitis, pneumonia; 42 year old male; 1996 Petteri Carlson
AhS23 Biotype S; diabetic foot gangrene; 45 year old male; 1997 Petteri Carlson
AhS24 Biotype S; tonsillitis; 16 year old female; 1998 Petteri Carlson
AhS25 Biotype S; metatarsal osteitis; 37 year old male; 1998 Petteri Carlson
AhR26 Biotype R; wound infection; 43 year old male; 1991 Petteri Carlson
AhR27 Biotype R; wound infection; 53 year old male; 1991 Petteri Carlson
AhR28 Biotype R; pharyngitis; 13 year old female; 1991 Petteri Carlson
AhR29 Biotype R (uncertain); peritonsillar abscess; 18 year old male;
1991
Petteri Carlson
AhR30 Biotype R; sinusitis; 14 year old male; 1992 Petteri Carlson
AhR31 Biotype R; peritonsillar abscess; 21 year old male; 1986 Petteri Carlson
AhR32 Biotype R; peritonsillar abscess; 15 year old female; 1992 Petteri Carlson
AhR33 Biotype R; pharyngitis; 26 year old male; 1992 Petteri Carlson
AhR34 Biotype R; pharyngitis; 15 year old male; 1992 Petteri Carlson
AhR35 Biotype R; pharyngitis; 18 year old male; 1992 Petteri Carlson
AhR36 Biotype R; pharyngitis; 21 year old male; 1992 Petteri Carlson
AhR37 Biotype R; peritonsillar abscess; 15 year old female; 1992 Petteri Carlson
AhR38 Biotype R; wound infection; 21 year old female; 1992 Petteri Carlson
AhR39 Biotype R; pharyngitis; 18 year old female; 1992 Petteri Carlson
AhR40 Biotype R; pharyngitis; 17 year old male; 1992 Petteri Carlson
AhR41 Biotype R; pharyngitis; 24 year old male; 1992 Petteri Carlson
AhR42 Biotype R; pharyngitis; 16 year old female; 1992 Petteri Carlson
AhR43 Biotype R; pharyngitis; 12 year old male; 1992 Petteri Carlson
AhR44 Biotype R; pharyngitis; 18 year old male; 1992 Petteri Carlson
AhR45 Biotype R; pharyngitis; 16 year old male; 1992 Petteri Carlson
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vector pET28a (Novagen) using NheIa n dXhoIs i t e s
(underlined), and confirmed by sequencing. The plo
gene encoding PLO was amplified from T. pyogenes
ATCC 49698 DNA using the primers PYO28-F
(GCCGCCCATATGGCCGGATTGGGAAACAGTTCG)
and PYO-R (GCCGCCCTCGAGCTAGGATTTGA-
CATTTTCCTC), cloned into pET28a using NdeIa n d
XhoI sites (underlined), and confirmed by sequencing.
The ily gene encoding ILY was amplified from Strepto-
coccus intermedius and cloned into pET28a as described
[22]. Purification of the His-tagged CDCs was as pre-
viously described [22,23].
SDS-PAGE and Western blotting
Proteins were separated by electrophoresis in 10% (w/v)
SDS-polyacrylamide gels and transferred to nitrocellu-
lose [15]. Western blots were immunostained using rab-
bit anti-His-ALN (prepared by immunization of a rabbit
with His-ALN, Antibodies Inc., Davis, CA) and rabbit
anti-goat IgG(H+L)-peroxidase conjugate (KPL), as the
primary and secondary antibodies, respectively. Rabbit
antiserum against PFO was kindly provided by Rodney
K. Tweten, University of Oklahoma Health Sciences
Center, OK.
Hemolytic assays
The hemolytic titers of His-ALN preparations were
determined by incubation of two-fold serial dilutions of
protein with an equal volume of 0.5% blood (Cleveland
Scientific, Bath, OH) at 37°C for 1 h [14]. The hemolytic
titer was the reciprocal of the highest dilution which
resulted in 50% cell lysis, expressed as hemolytic units
(HU) [14]. The specific activity of purified His-ALN was
determined as HU/μg protein. Thiol activation was
assessed by incubation of 5 HU His-ALN with 2% b-
mercaptoethanol for 10 min at room temperature, prior
to performing a hemolytic assay with human blood (Cle-
veland Scientific). Cholesterol inhibition was assessed by
incubation of 5 HU His-ALN with 0.01-1 μMc h o l e s -
terol for 30 min at room temperature with shaking,
prior to performing a hemolytic assay with human
blood. Cholesterol was diluted in absolute ethanol and
an equal volume of ethanol was used as the cholesterol-
free control. His-tagged perfringolysin O (PFO) [24] and
His-tagged PLO [14] were used as controls in the var-
ious hemolytic assays. For some experiments hemolysis
assays were performed as described [22,23].
Epithelial cell cytotoxicity
The epithelial cell cytotoxicity of His-ALN was deter-
mined using the CellTiter 96
® Aqueous One Solution
Cell Proliferation Assay (Promega). A549 (human lung,
CCL-185), CHO (hamster ovary, CCL-61), HCT-8
(human colon, CCL-244), J774A.1 (mouse macrophage,
TIB-67), MDBK (bovine kidney, CCL-22), MDCK
(canine kidney, CCL-34) and RK-13 (rabbit kidney,
CCL-37) cells were cultured in Iscove’s Modified Dul-
becco’s Medium or RMPI 1640 with 10% fetal bovine
serum and 10 μg/ml gentamicin in a humidified, 5%
CO2 atmosphere at 37°C. Cells were seeded into 96-well
plates at 2 × 10
4 cells/well and incubated for 18 h to
achieve 80% confluence. Triplicate wells were incubated
with doubling dilutions of His-ALN (0-2000 ng) and
incubated for 2 h, prior to addition of substrate for 3 h.
Determination of cell viability was performed using the
appropriate control values (Promega).
Membrane binding assay
The membrane binding assay was performed using ery-
throcytes as previously described [25]. His-ALN was
diluted to 12.5 μgm l
-1 in PBS, 40 μl was added to an
equal volume of 50% (v/v) blood and the mixture was
incubated on ice for 20 min. Cells were harvested by
centrifugation at 14,000 g for 5 min at 4°C, resuspended
in SDS-PAGE sample buffer and subjected to SDS-
PAGE and Western blotting with antiserum against His-
ALN.
Table 1 Arcanobacterium strains used in this study. (Continued)
AhR46 Biotype R; pharyngitis; 14 year old female; 1992 Petteri Carlson
AhR47 Biotype R; pharyngitis; 13 year old female; 1991 Petteri Carlson
AhR48 Biotype R; pharyngitis; 15 year old male; 1992 Petteri Carlson
AhR49 Biotype R; pharyngitis; 20 year old male; 1991 Petteri Carlson
AhR50 Biotype R; pharyngitis; 19 year old female; 1992 Petteri Carlson
CCUG39796 Biotype unknown; infected leg ulcer; 52 year old male; 1998 Petteri Carlson
ATCC9345; DSM 20595 Biotype unknown, 1946 American Type Culture Collection;
[12]
Trueperella (Arcanobacterium) pyogenes
BBR1
plo nanH nanP cbpA fimAB tet(W); Isolated from a bovine
abscess
[14]
* S, Smooth type; R, rough type.
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Cloning and nucleotide sequence determination of aln
A draft genome sequence of A. haemolyticum ATCC
9345 was determined and consists of 46 contigs that
encompass ~1.945 Mb in size (D. J. McGee, S. J. Billing-
ton, and B. J. Jost, unpublished). 1,639 ORFs were preli-
minarily identified using the Rapid Annotation using
Subsystem Technology (RAST) Server [26]. Within this
sequence, we identified ORF Arch_1062, the translation
of which displayed similarity to other CDCs. The 1,710
bp gene was designated aln, for arcanolysin (ALN).
Upstream of aln are a phosphoglycerate mutase gene
(pgm; Arch_1063) (EC 5.4.2.1) and an alanine tRNAGGC
(Figure 1). In the 426 bp intergenic region are regulatory
signals predicted to be involved in aln transcription,
including a putative s
70 promoter and 3 direct repeats
(ATTTT(G/C)(G/T)T) which are similar to those found
immediately upstream of plo, encoding PLO, the CDC
of T. pyogenes [27]. 6 bp downstream of aln is a
transcriptional terminator with a ΔG = -18.05 kcal/mol.
Downstream of aln and divergently transcribed is
Arch_1061. The Arch_1061 protein displays amino acid
similarity to hypothetical proteins from a number of
genome sequences, including Corynebacterium jeikeium
(GenBank YP_249820.1), and features a signal sequence.
Further downstream is an additional alanine tRNACGC,
which is 91% identical at the nucleotide level to the ala-
nine tRNAGGC upstream of aln. Further downstream of
the 2
nd alanine tRNA is Arch_1060, a gene that is pre-
dicted to encode a conserved hypothetical protein
related to Corynebacterium diphtheriae (DIP0761), and
a gene, Arch_1059 (ubiE), with similarity to type II or
SAM-dependent methyltransferases (EC 2.1.1.-).
The %G+C for aln is 46.7% (Figure 1) compared with
49.7-60.3% for the surrounding genes and 53.1% for the
entire genome. Given the lower %G+C of the aln gene
and the presence of flanking tRNA genes, which can act
as sites of foreign gene insertion [28], it is possible that
Figure 1 Map of the A. haemolyticum aln region and presence of aln in clinical isolates.( a )M a po ft h ealn gene region of strain ATCC
9345 (= DSM20595 = 11018). The open arrows indicate the gene and the direction of transcription. Gene names are given and the number
indicates the %G+C of the gene. A bar indicating 1 kb is shown on the right. (b) DNA dot hybridization of genomic DNA from A. haemolyticum
strains with an aln-specific probe. Genomic DNA from 52 A. haemolyticum isolates and T. pyogenes BBR1, as a negative control (~500 ng each),
was spotted onto a nylon membrane and hybridized with aln-specific probe under high stringency conditions. A. haemolyticum ATCC9345 DNA
is in the second from last spot. T. pyogenes BBR1 DNA is in the last spot.
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tal gene transfer.
aln is widely distributed in A. haemolyticum isolates
The prevalence of the aln gene was determined by DNA
hybridization. A DIG-labeled probe spanning bases 492-
1,052 of the aln ORF was hybridized to genomic DNA
from A. haemolyticum ATCC9345, 51 A. haemolyticum
clinical isolates (Table 1) and T. pyogenes BBR1, as a
negative control. The aln probe hybridized at high strin-
gency to all A. haemolyticum isolates (n = 52), but not
T. pyogenes g e n o m i cD N A( F i g u r e1 b ) ,i n d i c a t i n gt h a t
this gene appears to be highly prevalent in A. haemolyti-
cum. The region of aln from which the probe was
derived has 62.8% identity to the corresponding nucleo-
tide region in plo of T. pyogenes. Under high stringency
hybridization conditions, DNA sequences which are less
than 70% identical do not hybridize.
Analysis of the primary structure of ALN
The predicted ALN protein is 569 amino acids in
length, including a 26 amino acid signal sequence pre-
dicted by SignalP. The mature protein lacking the signal
sequence has a predicted molecular mass of 60.1 kDa.
ALN is most similar to PLO with 59.4% and 71.5%
amino acid identity and similarity (Figure 2) and has
~50% similarity to other CDC family members. Within
the ALN N-terminus, the pestfind algorithm identified a
putative PEST sequence not present in PLO or most
other CDC sequences (Figure 3a). Listeriolysin O (LLO),
which contains a bona fide PEST sequence [29],
returned a pestfind score of 4.71, while ALN had a
score of 7.58, indicating a higher probability of contain-
ing a functional PEST sequence. Given that A. haemoly-
ticum invades host cells [9], it is possible that the PEST
sequence allows for a similar compartmentalization of
ALN activity within the host cell. Like PLO, the pre-
dicted amino acid sequence of ALN has a variant unde-
capeptide in domain 4 and both lack the conserved
cysteine residue (Figure 3b). The tryptophan spacing of
ALN and PLO (WxxWW) also differs from the consen-
sus sequence (WxWW) (Figure 3b).
Cloning and expression of His-ALN
SDS-PAGE and Coomassie Brilliant Blue staining of
IPTG-induced cultures of pBJ51-containing E. coli indi-
cated the presence of an over-expressed protein of ~64
kDa (Figure 4a). His-ALN was purified to > 95% homo-
geneity using TALON resin (Figure 4a), and the size of
this protein (~64 kDa) corresponded to its predicted
molecular mass. Antiserum against ALN, but not pre-
immune antiserum, reacted specifically with His-ALN
and some possible HIS-ALN degradation products (Fig-
ure 4b and 4c).
Figure 2 Neighbor joining tree of amino acid sequences
showing the relationship of ALN to other selected CDC family
members. Abbreviations and gi ascession numbers from the NCBI
protein database: ALN, arcanolysin (259156857); PLO, pyolysin
(2252800); LLO, listeriolysin O (16802248); SLG seeligeriolysin
(40889013); TET, tetanolysin (28211522); SLO, streptolysin O
(15674372); PFO, perfringolysin O (18309145); SPH, sphaericolysin
(146455206); CER, cereolysin (62550724); ALO, anthrolysin O
(49186114); PLY, pneumolysin (15901747); ILY, intermedilysin
(6729344); VLY, vaginolysin (187940699); LLY, lectinolysin
(190576835); INY, inerolysin (259167149); SLY, suilysin (253752120).
Figure 3 Salient features of the ALN predicted amino acid
sequence. (a) ALN sequence with predicted signal sequence
(underlined), putative PEST motif (inverse), undecapeptide (bold),
and cholesterol-interacting TL motif (double underlined). (b)
Undecapeptide sequences of ALN, other CDC undecapeptides
known to differ from consensus, and the consensus CDC
undecapeptide. The cysteine conserved in thiol-activated CDCs (but
absent from ALN) is underlined in the consensus sequence.
Differences from consensus depicted as inverse letters.
Abbreviations as in Figure 2.
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A. haemolyticum is not strongly hemolytic when grown
on ovine (sheep) blood agar [10]. Likewise, the E. coli
strain expressing His-ALN did not display hemolysis
when grown on bovine blood agar (data not shown).
Similarly, His-ALN displays low hemolysis with bovine
or ovine erythrocytes (Figure 5a). In contrast, His-ALN
had ~4- and 10-fold increased hemolytic activity on rab-
bit and human erythrocytes, respectively (Figure 5a).
This is in contrast to PFO or PLO, which show little dif-
ference in specific activity on erythrocytes from different
hosts. Consistent with these findings, hemolysis assays
demonstrated that ALN has a preference for horse or
human cells over porcine cells but lyses all of these at
high toxin concentrations (Figure 5b). This is in contrast
to intermedilysin (ILY) from Streptococcus intermedius,
which retains human-specific tropism over a wide con-
centration range, and PLO, which is less selective than
ALN (Figure 5b).
The highly-conserved Cys residue in the undecapep-
tide of CDCs is responsible for Thiol activation of this
group of toxins [30]. ALN lacks the Cys residue in the
undecapeptide (Figure 3a), and like PLO [14], its activity
was unaffected by treatment with b-mercaptoethanol
(data not shown).
We also determined the effect of recombinant ALN
on cultured mammalian cells. His-ALN was applied to
human, bovine, canine, hamster, mouse and rabbit cell
lines and was highly active on human and rabbit cells
(Figure 5c), with low activity on bovine, mouse and
canine cells. This toxin had intermediate activity on
hamster cells (Figure 5c). This finding mirrors the activ-
ity of ALN on blood from different host species (Figure
5a), and is less species-specific than intermedilysin (ILY)
or vaginolysin (VLY) [23,31]. ILY, VLY, and lectinolysin
(LLY) use human CD59 (hCD59) as a membrane recep-
tor [23,32,33], leading to host-specificity. Unlike these
other CDC toxins ALN hemolysis was not blocked with
a monoclonal antibody against hCD59 (data not shown).
Consistent with this finding, the predicted ALN amino
acid sequence lacks the Tyr-X-Tyr-X14-Ser-Arg signa-
ture motif common to all known hCD59-dependent
CDCs [33].
The activity of ALN is less sensitive to cholesterol
inhibition than PFO
Given the more restrictive host species preference of
ALN over that of PFO, along with the variant undeca-
p e p t i d es e q u e n c ei nA L N ,w eh y p o t h e s i z e dt h a tA L N
might be less sensitive to inhibition by free cholesterol.
As expected, PFO activity was almost completely inhib-
ited by exogenous 0.5 μM cholesterol (7.6%; Figure 6).
In contrast, PLO and ALN retained 52.5% and 41.4%
activity, respectively, when incubated with 0.5 μMc h o -
lesterol and retained ~20% of hemolytic activity at 1 μM
cholesterol (Figure 6). These data indicate that ALN and
PLO have intermediate sensitivity to cholesterol com-
pared to a CDC (PFO) with the conserved undecapep-
tide sequence.
ALN binds differentially to host cell membranes
Hemolytic assays measure the full spectrum of CDC
binding, oligomerization and pore formation leading to
cell lysis. However, initial toxin binding to membranes
can be determined by incubation of CDCs with host
cells at 4°C, which prevents subsequent oligomerization
and pore formation [34]. Using this approach, His-ALN
bound to human and rabbit erythrocytes as determined
by Western blotting (Figure 7). Probable ALN degrada-
tion products were also detected. His-ALN did not exhi-
bit detectable binding to bovine or ovine erythrocyte
membranes under these conditions. As a control, His-
PFO was incubated with human, bovine, ovine or rabbit
erythrocytes, and bound toxin was detected with anti-
PFO antiserum. His-PFO bound to all cell types at
approximately equivalent amounts (data not shown).
These data suggest that ALN host preference may occur
at the initial contact of the toxin with the host cell
membrane.
Discussion
T h eC D C sa r eaf a m i l yo fb a c t e r i a lt o x i n sp r o d u c e db y
diverse Gram-positive bacteria and are generally impor-
tant in pathogenesis [35-37]. CDCs have a four-domain
structure and a conserved C-terminal undecapeptide
sequence in domain 4 that is important for toxin func-
tion. Soluble CDC monomers bind to host membrane
targets, oligomerize into a large homomeric structure
Figure 4 Overexpression and purification of His-ALN. Whole-cell
lysates of IPTG-induced cultures of DH5aMCR(pTrcHis B) (lane 1)
and DH5aMCR (pBJ51) (lane 2) and 500 ng purified His-ALN (lane 3)
were subjected to SDS-PAGE. Separated proteins were stained with
Coomassie brilliant blue (a) or were transferred to nitrocellulose by
Western blotting and immunostained with 1/5000 rabbit pre-
immune serum (b) or rabbit anti-His-ALN (c). The position of the
~64 kDa His-ALN band is indicated by the arrow. Molecular mass
markers (kDa) are indicated on the left.
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pore, leading to cytolysis of target cells [38]. CDCs
interact with membrane cholesterol through a conserved
threonine-leucine pair in domain 4, and this interaction
is crucial to the formation off u n c t i o n a lp o r e s[ 3 9 ] .
Some CDCs, including ILY, VLY, and LLY, require the
presence of hCD59 as a membrane receptor, conferring
human-specific activity [23,33,40]. Among the CDCs,
P L Oi su n u s u a l ,a si tc o n t a i n sav a r i a n to ft h eh i g h l y
conserved domain 4 undecapeptide, and this divergent
Figure 5 ALN has differential activity on cells from various mammalian species.( a )T h es p e c i f i ca c t i v i t i e so fA L Nw e r ed e t e r m i n e db y
incubation of dilutions of His-ALN with erythrocytes from different host species. Results are an average of at least three independent
experiments conducted in duplicated and error bars represent standard deviation. (b) The species selectivity of ALN was compared to ILY and
PLO in hemolysis assays using human (square), horse (triangle), and pig (inverted triangle) erythrocytes. Representative of two experiments
conducted in triplicate and error bars represent standard error of the mean. (c) Dilutions of His-ALN were added to cultured host cells and the
amount of ALN required to reduce the cell viability by 50% was determined using the CellTiter 96
® Aqueous One Solution Cell Proliferation
Assay (Promega). Error bars indicate one standard deviation from the mean calculated from the averages of at least three independent
experiments conducted in triplicate.
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Page 8 of 11sequence is essential for full PLO activity [41]. The ALN
undecapeptide is most similar to that of PLO (Figure
3B), in that it retains the three tryptophan residues of
the consensus undecapeptide but employs an alternate
spacing (i.e. WxxWW rather than WxWW). The trypto-
phan residues of the undecapeptide are known to be
important for insertion of domain 4 into host cell mem-
branes [42]. Like the human-specific CDCs (VLY, ILY,
and LLY), ALN contains a proline in its undecapeptide
sequence. However, the hemolytic activity of ALN was
not blocked by antibodies to human CD59, which acts
as a receptor for the human-specific CDCs [23,32,33],
suggesting that ALN may interact with a distinct mem-
brane receptor, perhaps in addition to cholesterol. The
nature of the ALN receptor is currently unknown and is
under investigation. Although the cysteine residue in the
consensus undecapeptide confers the property of thiol
activation to CDCs, the cysteine is not essential for
streptolysin O and pneumolysin toxin function [43,44].
The human-specific CDCs (VLY, ILY, LLY), PLO, and
ALN all lack this conserved cysteine residue, but the
contribution of this sequence variation to toxin function
is not yet known for these toxins.
Some CDCs have a number of functions beyond sim-
p l ep o r ef o r m a t i o n .Streptococcus pyogenes uses strepto-
lysin O to introduce a bacterial effector into host cells
via a novel mechanism termed cytolysin-mediated trans-
location (CMT) [45]. At sublytic concentrations, CDCs
may act as ligands for toll-like receptors [46,47] and
may induce a cycle of p38 mitogen-activated protein
kinase (MAPK) phosphorylation and dephosphorylation
[48,49]. LLO allows Listeria monocytogenes to escape
from the vacuole into the cytoplasm where the organism
can rapidly multiply [50]. The site-specific nature of
LLO is controlled by cytosolic down-regulation of LLO
function due to an N-terminal PEST-like sequence,
which usually targets eukaryotic proteins for cytosolic
degradation. The PEST sequence results in a substan-
tially reduced half-life of LLO in the cytoplasm of the
host cell [29].
Conclusions
ALN has several unique features among the CDC family.
ALN has a variant undecapeptide and possesses an unu-
sual N-terminal extension, with a putative PEST
sequence. Moreover, ALN lacks the conserved cysteine
of thiol-activated CDCs, explaining why b-mercaptotha-
nol had no effect on ALN function. The unique
sequences and predicted structural features of ALN will
make it an interesting toxin to conduct future structure-
function analyses to identify additional unique proper-
ties of this toxin. ALN displays an unusual pattern of
target cell species selectivity, with high activity against
human, horse, and rabbit cells and lesser activity against
cells derived from other species. This selectivity appears
to function at the level of membrane binding and may
contribute to the host range of A. haemolyticum.
Further work will focus on understanding the role of
ALN in A. haemolyticum pathogenesis.
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